Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. - Wikidata - awgldk - TriplyDB

Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan.

Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan.

http://www.wikidata.org/entity/Q43292520

about

Options for Controlling Type 2 Diabetes during Ramadan Filling the Knowledge Gap in Diabetes Management During Ramadan: the Evolving Role of Trial Evidence Strategies to Make Ramadan Fasting Safer in Type 2 Diabetics: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials and Observational Studies Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients Randomized controlled clinical trial of a combination therapy of vildagliptin plus an α-glucosidase inhibitor for patients with type II diabetes mellitus.A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.Predetermined Anti-Diabetic Drug Regimen Adjustments during Ramadan Fasting: An Observational Study of Safety.The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study.Diabetes and Ramadan: an update on use of glycemic therapies during fasting Ramadan and diabetes: As-Saum (The fasting).The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial.Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan.Role of oral hypoglycemic agents in the management of type 2 diabetes mellitus during Ramadan.Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study.Effect of Vildagliptin Versus Sulfonylurea in Muslim Patients with Type 2 Diabetes Fasting During Ramadan in Egypt: Results from VIRTUE Study Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial.Vildagliptin vs sulfonylurea in Indian Muslim diabetes patients fasting during Ramadan Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan Experience with Vildagliptin in Type 2 Diabetic Patients Fasting During Ramadan in France: Insights from the VERDI Study.Glycemic effects of vildagliptin in patients with type 2 diabetes before, during and after the period of fasting in Ramadan.The diabetic patient in Ramadan.Safety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis.Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients Is gliclazide a sulfonylurea with difference? A review in 2016.The effect of vildagliptin relative to sulfonylurea as dual therapy with metformin (or as monotherapy) in Muslim patients with type 2 diabetes fasting during Ramadan in the Middle East: the VIRTUE study.Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management Sodium glucose co transporter 2 inhibitors and Ramadan: Another string to the bow.Diabetes and Ramadan: A concise and practical update.A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial.Ramadan: type 2 diabetes and risk of hypoglycaemia.Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2-I) During the Month of Ramadan in Muslim Patients with Type 2 Diabetes.Effectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial.

P2860

Q26752613-FA85BA95-6AF9-4AB7-BFF1-F4A03507F669 Q26752669-444F11A9-0EEC-442E-8E58-31AA652EA1C8 Q26772054-248D3ABC-5CF9-44FE-AD8F-642DC23052C4 Q28067209-2C2828D4-07C3-4A96-9784-1744FA7AC8BE Q33706160-583AFAA1-8E6F-4AB8-8696-A56F5017E81B Q33710159-37CC7CE3-178B-4D66-B703-ECCCCB782E6E Q33889887-1CCC2A89-2C93-434C-B429-C4CFB6C12AE6 Q34502809-AEF5FB94-83CF-4724-85C2-DBE8692DE364 Q35165826-518B8F00-4080-4E2C-A245-6BE30A732F6D Q35352472-9C39030F-7F9B-458B-A6BB-B6347D3B81B3 Q35659489-CC464523-1A0D-4010-99E1-B2AE632405F7 Q35997284-1918753A-17A5-4F39-ADEE-E1247A9DC6BA Q36107741-69C618D4-9D50-4B99-9F51-614AF606E0BE Q36670946-C0E56849-373A-47D0-ABF6-8FEAF8D82FCD Q37142980-DD10BB80-D0F3-45D0-95A3-A0F3A3819EC4 Q37239317-D80C3BDA-76BA-47C9-9822-39BB1D7B8135 Q37394223-CCD3697E-3E00-47F9-8353-956A4E63C43B Q37417767-446F901A-49B4-4D76-A441-A73AB2853950 Q37427512-3A23CBD4-45C0-43AF-9D8E-5A9250B0199F Q37468458-2D619377-B58B-4850-BEAA-1A22253F35F1 Q37679806-54E34DDB-3940-4066-93CF-EB07F73495EE Q37715182-08946E30-07A2-40F3-8F43-B2396323139E Q38380289-ED89220C-BC47-47F7-A23A-8FA994C99A91 Q38452890-FFBF99E8-8E26-4093-A263-367F32C8AFF3 Q38754132-E6E07039-2289-4AFB-AFE5-B8AEA2327C3A Q39339957-57B7DE49-B724-415B-AE7F-76B155814150 Q41826517-5DFAB5D6-190C-4BE5-B90F-B2CB983EC129 Q42058464-661B7B16-2D84-4537-BD54-417721DDA4C2 Q42239627-53EBEFE2-3AFE-4285-B52D-87117D099370 Q44197835-40A422A1-448F-464D-876F-F2BD09F8A454 Q44946002-3682EC19-DE72-4B94-A82D-1128955C7203 Q52587186-322F3598-6EBB-4F4A-9350-30602945F9CC Q52590747-B19BB0B7-6A84-434C-8D60-69005F3A221B

P2860

Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan.

http://www.wikidata.org/entity/Q43292520

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan.

@en

Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan.

@nl

type

label

Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan.

@en

Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan.

@nl

prefLabel

Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan.

@en

Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan.

@nl

P1433

Q43292520-614A12E1-25F7-4A7B-AB4F-C3D9719CB6F5

P1476

Q43292520-D0D42667-6654-40E7-AF9D-B82C6445FD28

P2093

Q43292520-320FCB18-E47D-4543-9147-18250B4A72AE

Q43292520-3FE40C14-7A39-4980-8BDF-1B642DB25998

Q43292520-6A2FAC2B-B169-46B1-95BC-DAE0D591D4FE

Q43292520-B4ACD229-98B3-45C6-AE08-00D7D685CF56

Q43292520-B70BF90D-9E86-4D67-A797-8B476F8D2986

Q43292520-E9F071E8-D068-4E50-9274-4F973B267DC8

Q43292520-ED8F020B-D849-4911-BA69-1FFF45941238

P304

Q43292520-F4AA3C49-8535-4518-A6D9-0B112F2EF791

P31

Q43292520-4B4E9C1E-CFC8-4EBB-81FD-98EA386370C0

P356

Q43292520-AE86EC8B-C3F9-43EC-B0B9-EAA1F026E812

P433

Q43292520-A6961D5F-7BA8-4523-BD34-27B20A90EC04

P478

Q43292520-27BAE29A-8920-4399-8239-D5440D3D0334

P577

Q43292520-2504647B-A30D-4AC4-A3E1-6D40D739DA90

P5875

Q43292520-B886077E-88FB-42DC-8D18-8FFD53044997

P698

Q43292520-81F7DE3D-DBFD-4396-A0FD-1AADB86C221C

P921

Q43292520-26161BEF-789C-431B-BD82-254E26804258

Q43292520-7A4DA9BE-C907-4DC7-BDC8-D862C3F299E1

P356

J.1742-1241.2009.02171.X

P1433

International Journal of Clinical Practice

P1476

Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan.

@en

P2093

B Gohel

http://www.w3.org/2001/XMLSchema#string

D Devendra

http://www.w3.org/2001/XMLSchema#string

E Hui

http://www.w3.org/2001/XMLSchema#string

M Hassanein

http://www.w3.org/2001/XMLSchema#string

S Mehar

http://www.w3.org/2001/XMLSchema#string

S Salih

http://www.w3.org/2001/XMLSchema#string

V Bravis

http://www.w3.org/2001/XMLSchema#string

P304

1446-1450

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1742-1241.2009.02171.X

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26740176

http://www.w3.org/2001/XMLSchema#string

P698

19678856

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes